Skip to main content
Erschienen in: Clinical & Experimental Metastasis 6/2012

01.08.2012 | Research Paper

Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids

verfasst von: Sophya Konstantinovsky, Ben Davidson, Reuven Reich

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

CAS proteins and Ezrin, Radixin, Moesin (ERM) family members act as intracellular scaffolds and are involved in interactions with the cytoskeleton, respectively. Both protein families have previously been associated with metastasis and poor prognosis in cancer. Our group recently reported on the overexpression of EZR/VIL2 and BCAR1 and their protein products in breast carcinoma effusions compared to primary breast carcinoma. In the present study, the role of these two proteins was studied in semi-normal MCF10A cells and metastatic MDA-MB-231 breast carcinoma cells cultured in tri-dimensional (3-D) conditions that were hypothesized to reproduce the in vivo conditions of breast cancer metastasis. MCF10A cells formed spheroid-shaped colonies without any Matrigel invasion, while MDA-MB-231 cells displayed an invasive phenotype and showed satellite projections that bridged multiple cell colonies in 3-D culture. E-cadherin was expressed in MCF10A, but not in MDA-MB-231 cells. The temporal expression of ezrin and BCAR1/p130Cas at the mRNA and protein level differed in the two cell lines upon 3-D culturing on Matrigel. Upregulation of BCAR1/p130cas was observed in the transition of MDA-MB-231 from attached to detached culture. Silencing of Ezrin and p130Cas in MDA-MB-231 cells by short hairpin RNA resulted in decreased invasive potential, and p130Cas silencing further resulted in smaller spheroid/colony formation. Our data show that MCF10A and MDA-MB-231 cells differ in their ability to form spheroids, in expression of E-cadherin and in the expression of Ezrin and BCAR1/p130Cas in 3-D cultures on Matrigel, suggesting a role in tumor progression in breast carcinoma.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
2.
Zurück zum Zitat Wilkes JD, Fidias P, Vaickus L, Perez RP (1995) Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute. Cancer (Phila) 76:1377–1387CrossRef Wilkes JD, Fidias P, Vaickus L, Perez RP (1995) Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute. Cancer (Phila) 76:1377–1387CrossRef
3.
Zurück zum Zitat Hausheer FH, Yarbro JW (1985) Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12:54–75PubMed Hausheer FH, Yarbro JW (1985) Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12:54–75PubMed
4.
Zurück zum Zitat Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F (1998) Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 65:108–113PubMedCrossRef Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F (1998) Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 65:108–113PubMedCrossRef
5.
Zurück zum Zitat Fentiman IS, Millis R, Sexton S, Hayward JL (1981) Pleural effusion in breast cancer: a review of 105 cases. Cancer 47:2087–2092PubMedCrossRef Fentiman IS, Millis R, Sexton S, Hayward JL (1981) Pleural effusion in breast cancer: a review of 105 cases. Cancer 47:2087–2092PubMedCrossRef
6.
Zurück zum Zitat Dieterich M, Goodman SN, Rojas-Corona RR, Emralino AB, Jimenez-Joseph D, Sherman ME (1994) Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 38:945–952PubMed Dieterich M, Goodman SN, Rojas-Corona RR, Emralino AB, Jimenez-Joseph D, Sherman ME (1994) Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 38:945–952PubMed
7.
Zurück zum Zitat Banerjee AK, Willetts I, Robertson JF, Blamey RW (1994) Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 20:33–36PubMed Banerjee AK, Willetts I, Robertson JF, Blamey RW (1994) Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 20:33–36PubMed
8.
Zurück zum Zitat Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R (2004) Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients- a novel model for tumor progression. Clin Cancer Res 10:7335–7346PubMedCrossRef Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R (2004) Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients- a novel model for tumor progression. Clin Cancer Res 10:7335–7346PubMedCrossRef
9.
Zurück zum Zitat Davidson B, Reich R, Lazarovici P, Ann Flørenes V, Nielsen S, Nesland JM (2004) Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83:119–128PubMedCrossRef Davidson B, Reich R, Lazarovici P, Ann Flørenes V, Nielsen S, Nesland JM (2004) Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83:119–128PubMedCrossRef
10.
Zurück zum Zitat Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MTP, Bassarova A, Kvalheim G, Nesland JM, Reich R (2006) The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 102:453–461PubMedCrossRef Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MTP, Bassarova A, Kvalheim G, Nesland JM, Reich R (2006) The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 102:453–461PubMedCrossRef
11.
Zurück zum Zitat Konstantinovsky S, Smith Y, Zilber S, Tuft Stavnes H, Becker AM, Nesland JM, Reich R, Davidson B (2010) Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol 2010:969084PubMed Konstantinovsky S, Smith Y, Zilber S, Tuft Stavnes H, Becker AM, Nesland JM, Reich R, Davidson B (2010) Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol 2010:969084PubMed
12.
Zurück zum Zitat Bissell MJ, Hall HG, Parry G (1982) How does the extracellular matrix direct gene expression? J Theor Biol 99:31–68PubMedCrossRef Bissell MJ, Hall HG, Parry G (1982) How does the extracellular matrix direct gene expression? J Theor Biol 99:31–68PubMedCrossRef
13.
Zurück zum Zitat Schmeichel KL, Bissell MJ (2003) Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci 116:2377–2388PubMedCrossRef Schmeichel KL, Bissell MJ (2003) Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci 116:2377–2388PubMedCrossRef
14.
Zurück zum Zitat Defilippi P, Di Stefano P, Cabodi S (2006) p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 16:257–263PubMedCrossRef Defilippi P, Di Stefano P, Cabodi S (2006) p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 16:257–263PubMedCrossRef
15.
Zurück zum Zitat Tikhmyanova N, Little JL, Golemis EA (2010) CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci 67:1025–1048PubMedCrossRef Tikhmyanova N, Little JL, Golemis EA (2010) CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci 67:1025–1048PubMedCrossRef
16.
Zurück zum Zitat Fehon RG, McClatchey AI, Bretscher A (2010) Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 11:276–287PubMedCrossRef Fehon RG, McClatchey AI, Bretscher A (2010) Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 11:276–287PubMedCrossRef
17.
Zurück zum Zitat Debnath J, Brugge JS (2005) Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5:675–688PubMedCrossRef Debnath J, Brugge JS (2005) Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5:675–688PubMedCrossRef
18.
Zurück zum Zitat Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:84–96PubMedCrossRef Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:84–96PubMedCrossRef
19.
Zurück zum Zitat Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC (2004) The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 10:6194–6202PubMedCrossRef Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC (2004) The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 10:6194–6202PubMedCrossRef
20.
Zurück zum Zitat Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C (2007) Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 24:69–78PubMedCrossRef Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C (2007) Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 24:69–78PubMedCrossRef
21.
Zurück zum Zitat Tait L, Soule HD, Russo J (1990) Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res 50:6087–6094PubMed Tait L, Soule HD, Russo J (1990) Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res 50:6087–6094PubMed
22.
Zurück zum Zitat Brinkley BR, Beall PT, Wible LJ, Mace ML, Turner DS, Cailleau RM (1980) Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res 40:3118–3129PubMed Brinkley BR, Beall PT, Wible LJ, Mace ML, Turner DS, Cailleau RM (1980) Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res 40:3118–3129PubMed
23.
Zurück zum Zitat Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ (1989) Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 105:223–235PubMed Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ (1989) Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 105:223–235PubMed
24.
Zurück zum Zitat Roskelley CD, Desprez PY, Bissell MJ (1994) Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc Natl Acad Sci USA 91:12378–12382PubMedCrossRef Roskelley CD, Desprez PY, Bissell MJ (1994) Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc Natl Acad Sci USA 91:12378–12382PubMedCrossRef
25.
Zurück zum Zitat Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signaling: Tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287–309PubMedCrossRef Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signaling: Tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287–309PubMedCrossRef
26.
Zurück zum Zitat Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ (1992) Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89:9064–9068PubMedCrossRef Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ (1992) Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89:9064–9068PubMedCrossRef
27.
Zurück zum Zitat Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS (2001) ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3:785–792PubMedCrossRef Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS (2001) ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3:785–792PubMedCrossRef
28.
Zurück zum Zitat Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526–1535PubMedCrossRef Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526–1535PubMedCrossRef
29.
Zurück zum Zitat Gautreau A, Louvard D, Arpin M (2002) ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 14:104–109PubMedCrossRef Gautreau A, Louvard D, Arpin M (2002) ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 14:104–109PubMedCrossRef
30.
Zurück zum Zitat Gautreau A, Poullet P, Louvard D, Arpin M (1999) Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:7300–7305PubMedCrossRef Gautreau A, Poullet P, Louvard D, Arpin M (1999) Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:7300–7305PubMedCrossRef
31.
Zurück zum Zitat Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M (2003) Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell 14:2181–2191PubMedCrossRef Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M (2003) Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell 14:2181–2191PubMedCrossRef
32.
Zurück zum Zitat Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth MA (1999) High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 258:395–400PubMedCrossRef Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth MA (1999) High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 258:395–400PubMedCrossRef
33.
Zurück zum Zitat Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP (2001) Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61:1569–1577PubMed Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP (2001) Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61:1569–1577PubMed
34.
Zurück zum Zitat Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61:3750–3759PubMed Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61:3750–3759PubMed
35.
Zurück zum Zitat O’Neill GM, Fashena SJ, Golemis EA (2000) Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol 10:111–119PubMedCrossRef O’Neill GM, Fashena SJ, Golemis EA (2000) Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol 10:111–119PubMedCrossRef
36.
Zurück zum Zitat Giancotti FG (2003) A structural view of integrin activation and signaling. Dev Cell 4:149–151PubMedCrossRef Giancotti FG (2003) A structural view of integrin activation and signaling. Dev Cell 4:149–151PubMedCrossRef
37.
Zurück zum Zitat Wei L, Yang Y, Zhang X, Yu Q (2002) Anchorage-independent phosphorylation of p130(Cas) protects lung adenocarcinoma cells from anoikis. J Cell Biochem 87:439–449PubMedCrossRef Wei L, Yang Y, Zhang X, Yu Q (2002) Anchorage-independent phosphorylation of p130(Cas) protects lung adenocarcinoma cells from anoikis. J Cell Biochem 87:439–449PubMedCrossRef
38.
Zurück zum Zitat Radisky D, Hagios C, Bissell MJ (2001) Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 11:87–95PubMedCrossRef Radisky D, Hagios C, Bissell MJ (2001) Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 11:87–95PubMedCrossRef
39.
Zurück zum Zitat Weigelt B, Bissell MJ (2008) Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 18:311–321PubMedCrossRef Weigelt B, Bissell MJ (2008) Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 18:311–321PubMedCrossRef
40.
Zurück zum Zitat Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ (2006) Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 23:227–236PubMedCrossRef Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ (2006) Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 23:227–236PubMedCrossRef
Metadaten
Titel
Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids
verfasst von
Sophya Konstantinovsky
Ben Davidson
Reuven Reich
Publikationsdatum
01.08.2012
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 6/2012
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-012-9468-2

Weitere Artikel der Ausgabe 6/2012

Clinical & Experimental Metastasis 6/2012 Zur Ausgabe

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.